Check-Cap (NASDAQ:CHEK) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 1.8 %

CHEK stock opened at $0.60 on Thursday. Check-Cap has a 52 week low of $0.60 and a 52 week high of $3.45. The business has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.59. The company has a market cap of $3.51 million, a PE ratio of -0.20 and a beta of 0.25.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.